TABLE 1 | Emerging therapies for obesity in clinical development

From the following article:

Obesity market overview

Christine Farrigan & Kevin Pang

Nature Reviews Drug Discovery 1, 257-258 (April 2002)

doi:10.1038/nrd781

CompoundDevelopment phaseMarketing companyRegion
Leptin-related compounds
AxokineIIIRegeneronUnited States
Recombinant human leptinIIAmgenUnited States
Other new, centrally acting appetite suppressants
Rimonabant (SR-141716)IIISanofi-SynthélaboEurope
Bupropion SRIIGlaxoSmithKlineUnited States
P-57IIPhytopharm/PfizerEurope
Topiramate*DJohnson & JohnsonUnited States
Pancreatic-lipase inhibitors
ATL-962IAlizymeEurope
beta3-adrenoceptor agonists
SB-418790 (AZ-40140)IIGlaxoSmithKlineEurope
 PCAsahi KaseiJapan
LY-377604IEli LillyUnited States
N-5984INissin Kyorin PharmaceuticalJapan
Carboxypeptidase-enzyme inhibitors
MLN-4760IMillennium Pharmaceuticals/Abbott LaboratoriesUnited States
Cholecystokinin-A-receptor agonists
GI-181771IIGlaxoSmithKlineEurope
Thyroid-hormone-receptor agonists
Thyroid-hormone-receptor-betaIBristol-Myers SquibbUnited States
agonistIKaro BioEurope‡

Download file

If the slide opens in your browser, select "File > Save As" to save it.